Clinical efficacy of the oral Janus kinase inhibitor tofacitinib at Month 6 was greater than placebo and “appeared similar regardless of methotrexate dose” in patients with rheumatoid arthritis a post-hoc analysis presented at the 2015 ACR/ARHP Annual Meeting has found.
Your search for esrd returned 4 results
Long-term etanercept is associated with modestly better treatment retention rates than adalimumab among patients with rheumatoid arthritis (RA), according to an analysis of data from the RHUMADATA® clinical registry and database presented at the 2015 ACR/ARHP Annual Meeting.
A non-TNF-targeted biologic showed better efficacy than a second anti-TNF agent for patients with rheumatoid arthritis and insufficient response to TNF-inhibitors, according to research presented at the 2015 ACR/ARHP Annual Meeting.
Obese patients diagnosed with rheumatoid arthritis (RA) can improve disease control by losing weight, according to a study reported at the 2015 ACR/ARHP Annual Meeting.